X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2024 February 20, 2024 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy January 17, 2024 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis January 8, 2024 argenx Highlights 2024 Strategic Priorities January 2, 2024 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference 2023 December 20, 2023 argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus November 28, 2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia November 16, 2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis November 1, 2023 argenx to Present at Upcoming Investor Conferences November 1, 2023 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions October 31, 2023 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update October 24, 2023 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023 September 21, 2023 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »